Evome Medical Technologies Inc. (LNDZF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Evome Medical Technologies Inc. (LNDZF) trades at $0.00 with AI Score 60/100 (Grade B+). Evome Medical Technologies Inc. develops, manufactures, and distributes medical devices for pain management and physical therapy. Market cap: $5,981, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for LNDZF: LNDZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LNDZF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
LNDZF: 3/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Evome Medical Technologies Inc. (LNDZF) Healthcare & Pipeline Overview
Evome Medical Technologies Inc. focuses on developing and distributing medical devices for pain management and physical therapy across the Americas and internationally. With a diverse product portfolio and a negative P/E ratio, the company operates in a competitive market, emphasizing innovation in rehabilitation technology.
What Is the Investment Thesis for LNDZF?
Evome Medical Technologies Inc. presents a speculative investment opportunity in the medical device sector. With a negative P/E ratio of -2.20 and a negative profit margin of -23.9%, the company's current profitability is a concern. However, the gross margin of 32.6% indicates potential for improved profitability with better cost management and revenue scaling. The company's beta of 2.29 suggests high volatility relative to the market. Key growth catalysts include expansion into new geographic markets and the introduction of innovative products. The company's success hinges on its ability to navigate regulatory hurdles, secure market adoption of its products, and achieve sustainable profitability.
Based on FMP financials and quantitative analysis
LNDZF Key Highlights
- Gross Margin of 32.6% indicates potential for profitability improvements.
- Negative P/E ratio of -2.20 reflects current losses.
- Profit Margin of -23.9% highlights the need for cost optimization.
- Beta of 2.29 suggests high volatility compared to the market.
- Market Cap of 6K indicates a micro-cap company.
Who Are LNDZF's Competitors?
LNDZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| PLSM PLSM | $4.96 | +9.25% | $32.25M | 60 |
| ECOR electroCore, Inc. | $8.28 | -5.59% | $68.69M | 60 |
| XENT Intersect ENT, Inc. | $28.24 | +0.00% | 60 | |
| ALGN Align Technology, Inc. | $188.39 | +2.10% | $13.49B | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LNDZF's Key Strengths?
- Diverse product portfolio in pain management and rehabilitation.
- Distribution network in the Americas and internationally.
- Proprietary technology in rehabilitation devices.
- Focus on non-invasive treatment options.
What Are LNDZF's Weaknesses?
- Negative P/E ratio and profit margin.
- High beta indicating high volatility.
- Limited brand recognition compared to larger competitors.
- Dependence on regulatory approvals for new products.
What Could Drive LNDZF Stock Higher?
- Potential FDA approval for new rehabilitation device in Q4 2026.
- Expansion of distribution network into new geographic markets.
- Development of wearable technology for remote patient monitoring.
- Strategic partnerships with rehabilitation centers by Q2 2027.
What Are the Key Risks for LNDZF?
- Financial-distress signal — its Altman Z-Score of -3.77 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-44.2%) — the business is not currently generating profit on shareholder capital.
- Intense competition from established medical device companies.
- Stringent regulatory requirements and approval processes.
- Economic downturns affecting healthcare spending.
- Technological obsolescence and the need for continuous innovation.
- Negative P/E ratio and profit margin impacting financial stability.
What Are the Growth Opportunities for LNDZF?
- Expansion into Emerging Markets: Evome Medical Technologies Inc. can pursue growth by expanding its distribution network into emerging markets in Asia-Pacific and Latin America. These regions have a growing demand for advanced medical devices due to increasing healthcare expenditure and rising awareness of rehabilitation therapies. The market size for medical devices in emerging markets is projected to reach $200 billion by 2028, offering a significant opportunity for Evome to increase its revenue and market share. Timeline: 2-3 years.
- Development of Wearable Technology: Investing in the development of advanced wearable technology for remote patient monitoring and rehabilitation can drive growth. The wearable medical device market is expected to reach $30 billion by 2027, driven by the increasing adoption of telehealth and remote patient monitoring solutions. Evome can leverage its expertise in rehabilitation devices to create innovative wearable solutions that improve patient outcomes and reduce healthcare costs. Timeline: 1-2 years.
- Strategic Partnerships with Rehabilitation Centers: Forming strategic partnerships with leading rehabilitation centers and hospitals can enhance Evome's market reach and product adoption. These partnerships can provide access to a large patient base and facilitate the integration of Evome's devices into clinical practice. The market for rehabilitation services is growing at a rate of 5-7% annually, driven by the increasing prevalence of musculoskeletal disorders and neurological conditions. Timeline: Ongoing.
- Focus on Non-Invasive Pain Management Solutions: The increasing demand for non-invasive pain management solutions presents a significant growth opportunity for Evome. The market for non-invasive pain management devices is projected to reach $15 billion by 2025, driven by the growing awareness of the risks associated with opioid-based pain medications. Evome can capitalize on this trend by developing and marketing innovative non-invasive devices that provide effective pain relief without the side effects of traditional medications. Timeline: 1-2 years.
- Leveraging Telehealth Platforms: Integrating Evome's devices with telehealth platforms can expand its reach and improve patient access to rehabilitation services. The telehealth market is experiencing rapid growth, driven by the increasing adoption of remote patient monitoring and virtual consultations. By partnering with telehealth providers, Evome can offer its devices as part of comprehensive telehealth solutions, reaching a wider patient population and generating recurring revenue streams. Timeline: Ongoing.
What Opportunities Does LNDZF Have?
- Expansion into emerging markets.
- Development of wearable technology for remote patient monitoring.
- Strategic partnerships with rehabilitation centers.
- Increasing demand for non-invasive pain management solutions.
What Threats Does LNDZF Face?
- Intense competition from established medical device companies.
- Stringent regulatory requirements and approval processes.
- Economic downturns affecting healthcare spending.
- Technological obsolescence and the need for continuous innovation.
What Are LNDZF's Competitive Advantages?
- Proprietary technology in rehabilitation devices.
- Established distribution network in the Americas.
- Diverse product portfolio catering to various rehabilitation needs.
- Strong relationships with healthcare providers and rehabilitation centers.
What Does LNDZF Do?
Evome Medical Technologies Inc. is a medical device company specializing in the development, manufacture, and distribution of products for pain management and physical therapy. Founded with the vision of advancing rehabilitation technology, the company has evolved to offer a comprehensive range of devices designed for the prevention, treatment, and rehabilitation of the human body. Its product portfolio includes isokinetic dynamometers, perturbation gait trainers, balance assessment and recovery devices, neuromuscular electrical and transcutaneous electrical nerve stimulation (TENS) devices, ultrasound treatment devices, and wearable technology. These products are distributed throughout the Americas and internationally, targeting healthcare providers and patients seeking advanced solutions for pain management and physical rehabilitation. Evome Medical Technologies Inc. aims to improve patient outcomes through innovative medical devices and technologies, positioning itself as a key player in the medical device industry.
What Products and Services Does LNDZF Offer?
- Develops medical devices for pain management.
- Manufactures physical therapy equipment.
- Distributes products in the Americas and internationally.
- Offers isokinetic dynamometers for strength testing.
- Provides perturbation gait trainers for balance rehabilitation.
- Supplies neuromuscular electrical stimulation devices.
- Offers ultrasound treatment devices.
- Develops wearable technology for patient monitoring.
How Does LNDZF Make Money?
- Develops and manufactures medical devices.
- Sells products directly to healthcare providers and rehabilitation centers.
- Distributes products through a network of distributors in the Americas and internationally.
- Generates revenue from device sales and service contracts.
What Industry Does LNDZF Operate In?
Evome Medical Technologies Inc. operates within the medical device industry, a sector characterized by continuous innovation and stringent regulatory oversight. The market is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. Competition is intense, with established players and emerging companies vying for market share. Evome Medical Technologies Inc. focuses on the pain management and physical therapy segments, which are experiencing growth due to the increasing demand for non-invasive treatment options and rehabilitation services. The company's success depends on its ability to differentiate its products, navigate regulatory pathways, and establish strong relationships with healthcare providers.
Who Are LNDZF's Key Customers?
- Hospitals and rehabilitation centers.
- Physical therapists and chiropractors.
- Sports medicine clinics.
- Individual patients requiring pain management and rehabilitation.
Net buyingInsider Activity
The most recent 2 insider filings for Evome Medical Technologies Inc. break down as 0 sales and 2 purchases. On net that is roughly 75K shares acquired (about $41K) — insiders putting money in tends to read as conviction.
F-Score 4/9Financial Health
Evome Medical Technologies Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.77 places it in the distress zone, a signal of elevated financial risk.
ROE -44%Key Financial Metrics
Return on equity for Evome Medical Technologies Inc. stands at -44.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -45.6%, the inverse of the P/E and a quick read on earnings relative to price.
Evome Medical Technologies Inc. (LNDZF) Valuation Context
Valued at 6K, LNDZF is classified as a micro-cap stock. Relative to its peer group, LNDZF's quantitative score of 60/100 is roughly in line with the peer average of 69/100.
Company Profile
Evome Medical Technologies Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Shirley, US. The company is led by CEO Christopher Heath. LNDZF has traded publicly since 2015.
LNDZF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Evome's recent insider buying signals strong confidence from within, suggesting they believe the company is undervalued.
- The community buzz is leaning positive, with many seeing potential in their innovative medical solutions. It feels like early innings.
- Market perception is shifting; Evome is increasingly viewed as a disruptor in medical tech, not just another player.
- Their focus on specialized medical technologies positions them well for long-term growth in a niche market.
Bear Case
- Recent insider activity, while showing buys, is not overwhelmingly bullish; some insiders may be diversifying portfolios.
- Community sentiment, while positive, is cautious due to the speculative nature of the medical tech sector. Remember Theranos?
- Market perception is still heavily influenced by broader economic uncertainty affecting high-growth stocks.
- Competition in the medical tech space is fierce; Evome needs to prove its tech is truly differentiated to gain significant market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LNDZF Latest News
No recent news available for LNDZF.
LNDZF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LNDZF.
Price Targets
Wall Street price target analysis for LNDZF.
LNDZF MoonshotScore
What does this score mean?
The MoonshotScore rates LNDZF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Christopher Heath
CEO
Christopher Heath serves as the CEO of Evome Medical Technologies Inc. He has extensive experience in the medical device industry, with a background in strategic leadership and business development. Prior to joining Evome, Mr. Heath held various leadership positions at medical technology companies, where he focused on driving growth and innovation. He holds a degree in Business Administration and has completed executive education programs in healthcare management.
Track Record: Since assuming the role of CEO, Christopher Heath has focused on expanding Evome's product portfolio and strengthening its distribution network. He has overseen the launch of several new products and has implemented strategies to improve operational efficiency. Under his leadership, the company has navigated regulatory challenges and has positioned itself for future growth in the competitive medical device market.
LNDZF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Evome Medical Technologies Inc. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, which can increase investment risk. This tier is often associated with speculative investments and should be approached with caution.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility.
- Fewer regulatory requirements increase the risk of fraud or mismanagement.
- Higher potential for dilution through stock issuances.
- OTC Other status may deter institutional investors.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their track record.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal standing.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the company's operations and assets.
- Established product portfolio in pain management and rehabilitation.
- Distribution network in the Americas and internationally.
- Experienced management team led by Christopher Heath.
- Focus on innovative medical device technology.
LNDZF Healthcare Stock FAQ
What does Evome Medical Technologies Inc. do?
Evome Medical Technologies Inc. develops, manufactures, and distributes medical devices and products focused on pain management and physical therapy. Their product portfolio includes devices such as isokinetic dynamometers, gait trainers, and electrical stimulation devices, designed to aid in the prevention, treatment, and rehabilitation of the human body. The company operates in the Americas and internationally, targeting healthcare providers and patients seeking advanced rehabilitation solutions.
What revenue streams does Evome Medical Technologies Inc. have in healthcare?
Evome Medical Technologies Inc. generates revenue primarily through the sale of its medical devices, including isokinetic dynamometers, perturbation gait trainers, balance assessment devices, and electrical stimulation devices. Revenue is also derived from service contracts and maintenance agreements associated with these devices. Geographically, revenue is generated from sales in the Americas and internationally, with a focus on healthcare providers, rehabilitation centers, and individual patients.
How does Evome Medical Technologies Inc. navigate regulatory approval processes?
Evome Medical Technologies Inc. must adhere to stringent regulatory requirements set by agencies such as the FDA in the United States and similar bodies in international markets. The company's regulatory strategy involves rigorous testing and documentation to demonstrate the safety and efficacy of its medical devices. They likely maintain a dedicated regulatory affairs team to manage submissions, monitor compliance, and address any issues that may arise during the approval process. The specific details of their FDA/EMA regulatory track record and pending approvals are Unknown.
What are the main risks for LNDZF?
Evome Medical Technologies Inc. faces several risks, including intense competition in the medical device industry, stringent regulatory requirements, and the potential for technological obsolescence. The company's current negative P/E ratio and profit margin also pose financial risks. Additionally, economic downturns could affect healthcare spending and demand for its products. As an OTC-listed company, LNDZF also faces risks associated with lower liquidity and transparency.
What are the key growth drivers for Evome Medical Technologies Inc.?
Key growth drivers for Evome Medical Technologies Inc. include expansion into emerging markets, development of wearable technology for remote patient monitoring, and strategic partnerships with rehabilitation centers. The increasing demand for non-invasive pain management solutions and the integration of its devices with telehealth platforms also present significant growth opportunities. These initiatives aim to increase market reach, improve patient access to rehabilitation services, and generate recurring revenue streams.
What are the key factors to evaluate for LNDZF?
Evome Medical Technologies Inc. (LNDZF) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does LNDZF data refresh on this page?
LNDZF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LNDZF's recent stock price performance?
Evome Medical Technologies Inc. (LNDZF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio in pain management and rehabilitation. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited to market cap, P/E ratio, profit margin, gross margin, beta, and dividend yield.
- OTC disclosure status is unknown, limiting transparency.
- AI analysis is pending, indicating further insights may be available in the future.